Moreover, the tirzepatide, a novel dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) analogue, which performed well in phase III clinical trial, has been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for management of T2DM [5,10,11]. This evidence concerns the gene GCG and type 2 diabetes mellitus.